Inspirerend ondernemen. Juist als alles om je heen beweegt.
Voor de zomer stond de Twinning Participaties Adviesgroep in De Grolsch Veste stil bij Inspirerend Ondernemen. Een middag over groei, innovatie én de mindset die daarbij hoort.
Groundbreaking technology for the treatment of neurological diseases
Curix, a participation of Twinning Investments, is developing groundbreaking technology for the treatment of life-threatening and debilitating neurological diseases. This new technology makes it possible to temporarily open the blood-brain barrier, addressing one of the biggest challenges in neurology.
Arjan Olde Damink
With this technology, drugs for brain tumors and neurodegenerative conditions, such as Alzheimer’s and Parkinson’s disease, can be delivered more efficiently. The participation of Twinning Participaties allows Curix to develop an injector system suitable for initial clinical studies in humans. “Our ultimate goal is to contribute to the development of improved treatments for neurological diseases”, says Peter Frinking, managing director and chief scientific officer at Curix.
Brain conditions, including brain tumors and neurodegenerative diseases such as ALS and Alzheimer’s, Parkinson’s and Huntington’s disease, have a major impact on patients, their loved ones and society as a whole. The treatment of these conditions is often very drastic, and in the case of neurodegenerative diseases, options are mainly limited to symptom management, as no cure currently exists. When developing drugs for neurological diseases, one of the challenges that must be overcome is the blood-brain barrier. This highly-selective barrier consists of unique cells lining the tiny blood vessels in the brain and acts like a protective filter, preventing harmful substances in the blood from entering the brain. In almost all cases, drugs are also prevented from reaching the brain, which makes the effective treatment of neurological diseases all the more difficult.
Meer nieuws
Groundbreaking technology for the treatment of neurological diseases
Curix, a participation of Twinning Investments, is developing groundbreaking technology for the treatment of life-threatening and debilitating neurological diseases. This new technology makes it possible to temporarily open the blood-brain barrier, addressing one of the biggest challenges in neurology.
Twinning lid van branchevereniging NVP
Twinning is per oktober 2025 lid van de Nederlandse Vereniging van Participatiemaatschappijen (NVP). Ons NVP-lidmaatschap is als een keurmerk, dat staat voor kwaliteit en professionaliteit in private equity en venture capital.